Kornimate/medical-research-clean huggingface dataset:
effect of whole-body vibration on insulin resistance in obese postmenopausal women.

Conditions: Insulin Resistance

Summary: this study will be conducted to investigate the effect of whole-body vibration on insulin resistance in obese postmenopausal women

the prevalence of obesity has tripled over the past four decades, imposing an enormous burden on people's health. obesity is associated with premature mortality and is a serious public health threat that accounts for a large proportion of the worldwide non-communicable disease burden, including type 2 diabetes, cardiovascular disease, hypertension, and certain cancers. reported that "whole-body vibration (wbv) training has been established as a useful method to improve physical fitness in obese individuals. vibration stimulus during half squatting might suggest a long-term effect of wbv on the endocrine system. therefore, in this study, the aim to investigate the effect of whole-body vibration on insulin resistance in obese postmenopausal.

Eligibility criteria:
inclusion criteria: * all women were postmenopausal with no menses at least 1 year. * their ages were ranged from 50-60 years old. * their body mass index (bmi) \> 30 kg/m2. * they were not engaged in any other treatment program. exclusion criteria: * women with body mass index (bmi) \< 30 kg/m2. * any cardio-respiratory diseases. * diabetes mellitus. * with malignancy. * with severe hemorrhage, acute viral disease and mental disorders. * smokers. * women with life threatening disorders as renal failure
stroke imaging package study of intracranial atherosclerosis ( sips-icas )

Conditions: Acute Ischemic Stroke AIS; Intracranial Atherosclerosis ICAS

Summary: a prospective, multicenter, cohort study to explore the stroke mechanisms of symptomatic intracranial atherosclerosis, the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional mri sequences plus high-resolution magnetic resonance (hr-mri).

1. first-ever stroke patients attributed to intracranial artery stenosis (\> 50% or occlusion) within 7 days after onset will be prospectively enrolled in our study and undergo new imaging technique package assessment at baseline. 2. the imaging technique package includes conventional cranial mri （t1,t2,t2 flair,dwi), cranial magnetic resonance angiography (mra),high-resolution magnetic resonance (hr-mri) and susceptibility weighted imaging (swi) or t2\*-weighted imaging. 3. enrolled patients are recommended to receive aggressive medical management consisted of aspirin (100 mg daily) and clopidogrel (75 mg daily) for 3 months and rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management. 4. patients were followed up for mrs score, stroke recurrence, medication compliance and laboratory examination including blood routine tests, liver functions and creatine kinase et al at 3 months, 6 months and 12 months after stroke onset. additionally, patients are required to retake new hrmri imaging of brain at 6 months.remote patient education by we-chat will be performed. 5. our study aims to explore the stroke mechanisms of symptomatic intracranial atherosclerosis, the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional mri sequences plus hr-mri.

Eligibility criteria:
inclusion criteria: 1. age 35-80 years old 2. first-ever stroke patients confirmed by diffusion weighted imaging (dwi) attributed to intracranial artery stenosis (\> 50%) within 7 days after onset. 3. patients with stable vital signs. 4. patients who have underwent thrombolytic/intravascular therapy are allowed to enroll in the study. exclusion criteria: 1. patients with \> 50% ipsilateral carotid artery stenosis, cardiac embolism ,and any other stroke etiologies such as vasculitis, dissection or other causes. 2. patients with absolute/relative contraindication to mri (including but not confined to metal in the body and claustrophobia). 3. patients who cannot comply with mri exam. 4. patients who decline the consent.

Keywords: acute ischemic stroke intracranial atherosclerosis icas hrmri
safety, tolerance and efficacy of an oral nutritional supplement in chronic heart failure and chronic obstructive pulmonary disease patients

Conditions: Cachexia; Chronic Obstructive Pulmonary Disease; Chronic Heart Failure

Summary: to test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in patients with chronic heart failure (chf) or chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * diagnosis of chf or copd * current body weight less than 6 months ago * bmi \>=20 and \<=30 kg/m2 * chf: lvef \>=45% measured within the past 6 months * symptom status equivalent to nyha class ii to iv * biochemical abnormalities for total cholesterol, serum uric acid, abnormal high crp * on standard therapy of chf including ace inhibitors and beta blockers * copd: symptom status equivalent to gold standard class ii to iv * fev1 \< 80% * fev1/fev \< 70% exclusion criteria: * significant oedema in the time of screening and randomisation * concomitant inflammatory diseases * active infections including hiv and aids * liver failure * chronic renal failure (scr\>1.5mg/dl) or cardiac pacemaker * acute or chronic infections * insulin treated diabetes mellitus * patient with established diagnosis of cachexia * life expectancy of less than 6 months in the opinion of the investigator * medications that impair sex hormone synthesis, secretion or function * patients with psychiatric diseases * body weight loss \> 5% during the last 6 months or \> 10% during the last 10 months * suspected allergy to any component of the investigational product(s) * fish oil supplementation within 3 months prior to the study entry * taking vitamin supplements in doses greater than the recommended daily allowances
valvosoft first-in-man study in severe symptomatic aortic stenosis

Conditions: Aortic Valve Stenosis

Summary: this is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using valvosoft® pulsed cavitational ultrasound therapy (pcut) - first-in-man

cardiawave has developed a new non-invasive, real-time image-guided, therapeutic approach to treat patients suffering from calcified aortic stenosis. cardiawave's valvosoft device is a new ultrasound therapy based on a disruptive technology involving delivering an extremely precise and focused ultrasound beam to perform a reparative effect on the aortic valve leaflets, softening the valve's tissues, restoring leaflet mobility, and therefore improving the overall clinical status related to the aortic valve stenosis. this is a fim study

Eligibility criteria:
inclusion criteria: 1. subjects suffering from severe symptomatic aortic valve stenosis (including subjects with a bicuspid valve). 2. patient is not eligible for tavr/savr . 3. age ≥18 years. 4. subjects who are willing to provide a written informed consent prior to participating in the study. 5. subjects who can comply with the study follow up or other study requirements. 6. subject eligible according to clinical review committee - exclusion criteria: 1. subjects with any electrical device implanted. 2. subjects with unstable arrhythmia not controlled by medical treatment. 3. subjects with implanted mechanical valve in any position or bio prosthetic valve in aortic position. 4. subjects with complex congenital heart disease. 5. chest deformity. 6. cardiogenic shock. 7. history of heart transplant. 8. subjects requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after treatment. 9. thrombus in heart. 10. acute myocardial infarction (mi), stroke or transient ischemic attack (tia) within one month prior to enrolment\*. 11. subjects who are pregnant or nursing. 12. subjects who are participating in another research study for which the primary endpoint has not been reached. -

Keywords: symptomatic aortic valve stenosis ultrasound non-invasive
c5a receptor expression - covid-19 (c5-cov)

Conditions: COVID-19

Summary: the pathophysiology of ards is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. the complement system and anaphylatoxin c5a have shown central role in the recruitment of these pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. c5a acts via receptors c5ar and c5l2. this is a preliminary study aimed at studying the expression of the c5a receptor on myeloid cells in peripheral blood of patients with ards secondary to covid-19. this study has of primary objective to show there is an overexpression of the c5a receptor in patients with ards secondary to covid-19 compared to control patients (patients with covid-19 without respiratory distress and healthy volunteers). the medium-term objective is to develop a clinical trial to test the effectiveness of anti-c5ar antibody in this condition.

the pathophysiology of ards is linked to an uncontrolled inflammatory response at the level of alveolo-capillary membrane, mediated by neutrophils and mononuclear cells. the complement system and anaphylatoxin c5a have shown central role in the recruitment of these pro-inflammatory cells and more broadly in the genesis of cytokinic storm syndrome. c5a acts via receptors c5ar and c5l2. this is a preliminary study aimed at studying the expression of the c5a receptor on myeloid cells in peripheral blood of patients with ards secondary to covid-19. this study has of primary objective to show there is an overexpression of the c5a receptor in patients with ards secondary to covid-19 compared to control patients (patients with covid-19 without respiratory distress and healthy volunteers). the medium-term objective is to develop a clinical trial to test the effectiveness of anti-c5ar antibody in this condition.

Eligibility criteria:
inclusion criteria: for patients in resuscitation unit with ards linked to covid-19: * patient under invasive mechanical ventilation * pao2 / fio2 \<300 * pcr sars-cov-2 positive in a pharyngeal or respiratory sample for control patients with covid-19 without ards * oxygen flow always less than 5 l / min * pcr sars-cov-2 positive in a pharyngeal or respiratory sample * no passage in resuscitation unit * favorable evolution exclusion criteria: * minors * patient deprived of liberty * patient's refusal to participate at study * patient for whom therapeutic limitation measures such as non-admission to intensive care have been issued * medullar aplasia

Keywords: covid-19 ards c5a receptors
effects of air pollution exposure reduction by filter mask on heart failure

Conditions: Exposure to Pollution; Heart Failure

Summary: exposure to air pollution is associated with increase in cardiovascular morbidity and mortality. controlled human exposure studies have demonstrated impaired vascular function and heart rate variability on healthy volunteers. the aim of this study is to investigate the effects of reducting diesel exhaust inhalation on endothelial function, heart rate variability and cardiopulmonary stress testing in healthy volunteers and patients with chronic heart failure, by using a filter mask.

design and setting: double-blind randomised crossover studies in a university teaching hospital patients: 30 patients with stable heart failure (nyha i-iii) and 15 healthy volunteers interventions: all 45 subjects will be exposed to dilute diesel exhaust (pm2.5 of 300 mg/m3), filtered diesel exhaust (filter mask), or filtered air main outcome measures: endothelial function, heart rate variability, six-minute walking test and blood samples for inflammatory factors

Eligibility criteria:
inclusion criteria: * nyha i-iii; * left ventricle ejection fraction \< 50%; * clinical condition stable for more than three months prior to the randomization; exclusion criteria: * severe arterial hypertension; * severe pulmonary disease; * patients with pace-markers; * patients with constrictive pericarditis; * severe chronic kidney disease; * patients with pulmonary hypertension; * stroke within the last six months; * severe hepatic disease; * patients with musculoskeletal limitations to exercise; * patients with cardiac cachexia.

Keywords: air pollution heart failure endothelium autonomic dysfunction cardiopulmonary exercise test
does a single shot femoral nerve block alone produce appropriate pain relief?

Conditions: Post-operative Pain

Summary: the aim of this study is to compare the efficacy of the analgesic effect of the preoperative femoral nerve block alone versus combined femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks in patients after tka in the immediate postoperative period.

bupivacaine will be used for all the nerve blocks.

Eligibility criteria:
inclusion criteria: * asa i-iii * undergoing two tka * understanding pca protocol exclusion criteria: * skin infection near injection site * allergy to local analgesics * peripheral neuropathy * coagulopathy * dementia * proven opioid dependency
diabetes prevention among post-partum women with history of gestational diabetes

Conditions: Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus

Summary: the purpose of the star-mama intervention is to develop a patient-tailored telephone-base counseling intervention for young latino women who are at high risk of diabetes. the intervention will focus at the end of pregnancy and the 9 months post-partum period to improve education and behavioral counseling on nutrition and other related health topics . the following hypotheses will be formally tested: compared with controls at 9 months post-partum: 1. women in the star-moms program will have improved self-reported behavioral outcomes for minutes of physical activity, lower fat diet, and breast-feeding duration (in weeks); 2. women in the star-moms program will have improved diabetes prevention knowledge; 3. women in the star-moms program will have increased diabetes-relevant screening rates. women in the star-mama will have lost more weight than women in the control group.

the star-mama intervention builds on theoretical constructs found in social cognitive theory, theory of planned behavior, and theories of social support found to be effective in weight loss, physical activity and dietary change, based on a recent meta-analysis and other studies. the investigators proposed development of star-mama will incorporate specific behavior change techniques associated with these theories, including: "self-regulatory" intervention techniques (specific goal setting, prompting self-monitoring, providing feedback on performance, goal review), self-efficacy building intervention techniques (motivational interviewing, using decisional balance and relapse prevention), individual tailoring techniques (information on content and resources), and culturally tailored social support, and which incorporates family needs.

Eligibility criteria:
inclusion criteria: * postpartum latino women (english or spanish speakers) with history of gestational diabetes. * 18 years or older exclusion criteria: * do not have type 1 or type 2 diabetes. * do not have access to phone line or a cellphone to receive weekly calls of health coaching education over the phone.

Keywords: type 2 diabetes prevention in the post-partum behavior change among latinas, health coaching, motivational interviewing techniques
efficacy and physiology of nasal high flow therapy

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the effects of a nasal high-flow (nhf) therapy in patients with chronic obstructive hypercapnic respiratory failure are still not sufficiently known yet. the aim of this study is a step-by-step generation of physiological data about gas exchange and respiration under high flow therapy using a nasal cannula with an airvo 2 device to provide nhf, leading to an analysis of the effects of high flow on pco2 levels, exercise capacity, quality of life and gas exchange in a long term home treatment compared to a standard low flow long term oxygen therapy (lot). hypothesis: nhf and lot therapy show differences in measured mean overnight transcutaneous carbon dioxide partial pressure (pco2) after four weeks of treatment.

stage 1: respiratory physiology. aim of this stage is to investigate the effects of nasal high flow (nhf) therapy in patients in progressed stages of copd, by measuring physiologic parameters like tidal volume, breathing frequency and expiratory pco2 concentration. stage 2: efficacy of short term nhf. aim of this stage is to evaluate the efficacy of two flow rates (20 l/min and 35 l/min) regarding alveolar ventilation in overnight therapy. for this reason, patients will have two psg sleep studies during their hospital stay, under 20 l/min and 35 l/min nhf therapy in randomized order. stage 3: home care monitoring. aim of this stage is to compare long term influences of nhf and lot on pco2 levels randomised crossover, 4 weeks each treatment. stage 4: long term home care monitoring . aim of this stage is the long term follow up (12 month) of patients to examine the compliance of a sufficient nhf therapy. patients will retain the nhf therapy if they are responders (pco2 improvement in stage 3 of at least 2 mmhg with nhf versus lot) and willing and able to use nhf and a patient log. all patients will be monitored for the next 12 month. after 6 month there will be a control phone call.

Eligibility criteria:
inclusion criteria: * age 40-80 * male and female * copd patients with chronic respiratory insufficiency (ph \>7.35 and pco2 \> 50mmhg) * stable respiratory situation exclusion criteria: * decompensated heart, liver or kidney failure. * pregnancy or nursing period * participation in another clinical trial within the last 4 weeks * drug abuse * incapable of giving consent * known obstructive sleep apnea syndrome (osa) (ahi\>10) * noninvasive ventilation (niv) therapy

Keywords: high flow copd airvo
the effect of intraneural facilitation therapy on diabetic patients with peripheral neuropathy

Conditions: Diabetic Neuropathy

Summary: the purpose of this graduate student research study is to explore the effects of a new treatment known as intraneural facilitation (inf) on diabetes mellitus type 2 (dmt2) subjects who have moderate - severe below ankle neuropathy symptoms. since inf has shown success in the clinic and significant improvements have been found in a recent pilot study, this study aims to further explore these effects on dmt2 subjects suffering from dpn. the investigators would like to investigate if inf improves blood flow in the foot, if it decreases the pain and improves the sensation, and if it improves the overall quality of life.

the demographic data (age, height, gender, and weight) will be collected from each subject. all subjects will go through the following protocol: first, subjects will complete pre-testing measurements consisting of 5 tests; pain quality assessment scale, semmes-weinstein monofilaments, neurocom smart balance master, quality of life- diabetic neuropathy scale (qol- dn), and zeno walkway. patients will then be randomized into two groups and blinded by the treatment. patients who draw "group 1" will be given the inf treatment and patients who draw "group 2" will be given the sham treatment. patients will then be completing 3 weeks of inf treatment, or sham treatment for 3 visits per 3 week, totaling 9 treatment visits. post treatment, patients will then return for the same 5 measurements completed at baseline.

Eligibility criteria:
inclusion criteria: * patients with diabetes type 2 and diabetic peripheral neuropathy with no other known underlying disease * below ankle diabetic peripheral neuropathy symptoms (numbness, tingling, burning, sharp pain, increased sensitivity, etc.) * ≥10 on quality of life- diabetic neuropathy scale (qol- dn) * between age 50-75 years exclusion criteria: * patients with a medical condition that suggested possible decline in function over the next 6 months such as; a current regimen of chemotherapy, radiation therapy, or dialysis * any lower extremity amputations or wounds * documented active alcohol and/or drug misuse * known health conditions: end stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease and active inflammations * dm patients with inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy (cidp), proximal diabetes neuropathy, and autonomic neuropathies * patients with other types of neuropathies not associated with diabetes mellitus such as b12 deficiency, hypothyroidism, and uremia * other severe chronic medical condition requiring active treatment * morbidly obese patients * pregnancy (self reported)
respiratory dynamics during birth stabilization in preterm infants less than 32+6/7 weeks gestation

Conditions: Infant, Premature

Summary: approximately 50% of preterm infants less than 32 weeks require respiratory assistance at the time of transition at birth. for that stabilization during resuscitation is successful, it is essential for proper ventilation. this transition is performed with non-invasive respiratory support and administration of positive pressure ventilation to establish adequate functional residual capacity. the problem is that a peak inspiratory fixed during ventilation, and adequate tidal volume is assumed, but usually not measured, unable to correct the peak pressure to optimize ventilation and reduce lung damage. in addition, frequent adverse events may hinder or impair the effectiveness of the ventilation, with the consequent deterioration in the prognosis of the newborn.

hypothesis the ability to visualize the parameters and curves respiratory flow, tidal volume and air pressure by respiratory monitoring with mfr during cardiopulmonary resuscitation in newborns in the delivery room, decreases at least 10% surfactant need in first 72 hours of life. evaluation data collection will be made prospectively. investigators will measure the parameters of lung mechanics (tidal volume expiratory airflow (tve), peak inspiratory pressure (pip), pressure at the end of exhalation (peep), inspiratory time (it)), in each of inflations administered to preterm with vpp or during the administration of continuous positive airway pressure (cpap) in spontaneous breathing, in the first 10 minutes after birth, recording the air leakage through the mask and obstructions. investigators also measure parameters of respiratory status and hemodynamic (fio 2, oxygen saturation, end tidal co2, respiratory rate, heart rate), patient monitoring during the implementation of the protocol, blood gases, manipulations of the airway during intervention and the onset of complications. patients will be randomize in a group 1, where these parameters of lung mechanics would be visible and other group 2, where the parameters of tve and respiratory flow would not be visible by the rescuer (the usual parameters of pip and peep will be visible). always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the spanish society of neonatology, based on international recommendations (1-3.5) apply. in turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks.

Eligibility criteria:
inclusion criteria: * infants less than 32+6/7 weeks gestational age, birth requiring stabilization with vpp or cpap in the delivery room. exclusion criteria: * congenital malformations or chromosomal aberrations * less than 22 weeks * birth-weight less than the third percentile for gestational age according to spanish curve * severe perinatal asphyxia (apgar score of 0-3 more than 5 min, cord blood ph\<7.00) * reanimation unrecorded with video * no obtained informed consent

Keywords: premature respiratory function monitor